Last reviewed · How we verify
NCT05205551: ProTECT
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
trial in Heart Transplant Rejection in 411 participants. Participants enrolled and being followed up; not accepting new ones.
31 October 2026
Quick facts
| Lead sponsor | Natera, Inc. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 411 |
| Start date | 1 October 2021 |
| Primary completion | 31 October 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Conditions studied
- Heart Transplant Rejection — all drugs for Heart Transplant Rejection →
Sponsor
Natera, Inc.
Who can join
18 and older, any sex, with Heart Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05205551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Transplant Rejection
Currently open trials in the same condition.
- NCT07531784 — A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplan · recruiting
- NCT05732779 — Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant R · NA · recruiting
- NCT06656065 — IMR-Heart Trasplant Study · recruiting
- NCT05184426 — MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) · active not recruiting
Other Natera, Inc. trials
Trials by the same sponsor.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07046585 — Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) · recruiting
- NCT06620627 — Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection · recruiting
- NCT05309382 — Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation · completed
- NCT05312814 — Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05205551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Natera, Inc.
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05205551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing